Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

作者
Yu Hu,Renchi Yang,Xiaofan Liu,Heng Mei,Hu Zhou,Shujie Wang,Ruibin Huang,Yi Wang,Xin Du,Jing Sun,Zeping Zhou,Zhenyu Yan,Wen-Ming Chen,Wei Wang,Qingchi Liu,Qingshu Zeng,Yuping Gong,Jie Yin,Xuliang Shen,Baodong Ye
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 2558-2558 被引量:1
标识
DOI:10.1182/blood-2024-204447
摘要

Introduction Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, showed a clinically meaningful sustained platelet response with a tolerable safety profile in adults with immune thrombocytopenia (ITP) in a randomized, double-blind, placebo-controlled phase 3 study (ESLIM-01) in China1. Here we reported the long-term safety and efficacy data of ESLIM-01 extension stage in a follow-on, open-label sub-study (NCT05029635). Methods ESLIM-01 enrolled adults with chronic primary ITP who failed to ≥1 prior ITP treatment, and the mean platelet counts (PLT) < 30×10⁹/L at 3 screening visits. Eligible patients (pts) were randomized (2:1) to receive sovleplenib 300 mg orally once daily (QD), or placebo for 24 weeks (wks). Pts who completed 24 wks of treatment, or did not respond during the first 12 wks of treatment in ESLIM-01 could be enrolled in an open-label sub-study to receive sovleplenib 300mg QD treatment. The long-term safety and efficacy were assessed in all treated pts with at least one dose of sovleplenib (all Sov group), including the cross-over pts from placebo (P-Sov group). The main efficacy endpoint of durable response was defined as: PLT ≥50 × 10⁹/L at ≥4 of 6 scheduled visits during wks 14 to 24 in ESLIM-01 or, PLT ≥50×10⁹/L at ≥ 2 of 3 protocol-defined visits during the second 12 wks of 24 wks in the open-label sub-study. Long-term durable response was defined as after receiving sovleplenib for 12 wks, PLT ≥ 50×109/L at ≥ 2 of 3 any 12-week consecutive protocol-defined visits. Overall response was defined as at least one PLT ≥50 × 10⁹/L under sovleplenib treatment. Any PLT impacted by rescue therapy was not considered for efficacy endpoint derivation. Results At data cutoff date (Jan 31, 2024), a total of 179 pts (all Sov) were treated with at least one dose of sovleplenib. Among them, 126 pts initially received sovleplenib and 53 pts (P-Sov) initially received placebo in ESLIM-01. 99 (55.3%) of 179 pts in all Sov group, and 28 (52.8%) of 53 pts in P-Sov group were still on the treatment in the sub-study. The median duration (min, max) of exposure was 56.6 wks (2.0, 105.3) in all sov group and 52.3 wks (2.0, 102.9) in P-Sov group. Baseline characteristics were generally similar between the two groups. The median age was 43.0 years in all Sov group and 41.0 years in P-Sov group, median duration from the first PLT reduction to the first sovleplenib dose was 7.7 years in all Sov group and 8.0 years in P-Sov group, and pts in both groups had a median of 4.0 lines of prior medications for ITP, including 72.6% and 67.9% of patients who received prior TPO/TPO-RA treatment in all Sov group and P-Sov group, respectively. An overall response was achieved by 145 of 179 pts (81.0%) in all Sov group, and 44 of 53 pts (83.0%) in P-Sov group. 92 pts (51.4%) in all Sov group, and 23 pts (43.4%) in P-Sov group achieved durable response, respectively. The durable response rates were highly consistent with that in sovleplenib group (48%) in ESLIM-011. Long-term durable response rate was 59.8% in all Sov group and 64.2% in P-Sov group. The median cumulative duration of PLT ≥50 × 10⁹/L (or ≥30 × 10⁹/L) was 38.9 wks (or 48.2 wks) in all Sov group, and 35.1 wks (or 43.4 wks) in P-Sov group. 22.9% of pts in all Sov group and 18.9% of pts in P-Sov group received rescue therapy. Compared to the data in ESLIM-01 (22% of sovleplenib vs. 35% of placebo)1, long-term treatment did not increase the patient proportion for rescue therapy. The incidence of major bleeding events per ISTH criteria in all Sov group was 2.2%, consistent with that of sovleplenib group in ESLIM-01. The most frequent (>1.0%) TRAEs of grade 3 or higher in all Sov group were alanine aminotransferase increased (4 [2.2%]), neutrophil count decreased (3 [1.7%]), gamma-glutamyltransferase increased (3 [1.7%]), aspartate aminotransferase increased (2 [1.1%]), and hypertension (2 [1.1%]); for P-Sov group, they were 1 (1.9%), 0, 1 (1.9%), 2 (3.8%), and 0, respectively. There were no deaths in ESLIM-01 extension stage. Conclusions Long-term treatment with sovleplenib was effective in increasing and maintaining platelet count with well tolerated safety in adults with chronic primary ITP in China. No new safety signals were identified. Key words: sovleplenib, immune thrombocytopenia, ITP, SYK inhibitor, SYK References: Yu Hu, et al. Lancet Haematol. 2024 Jun 13: S2352-3026(24)00139-X.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无奈枕头完成签到,获得积分10
刚刚
qingshui完成签到,获得积分10
1秒前
自觉夏彤完成签到,获得积分10
1秒前
butter完成签到,获得积分10
2秒前
一一完成签到 ,获得积分10
2秒前
Xccc完成签到,获得积分20
3秒前
立na完成签到,获得积分10
3秒前
3秒前
WN完成签到,获得积分10
4秒前
科研小将发布了新的文献求助10
5秒前
里工完成签到 ,获得积分10
6秒前
Gong完成签到 ,获得积分10
6秒前
繁荣的安白完成签到 ,获得积分10
7秒前
瘦瘦的枫叶完成签到 ,获得积分10
8秒前
嘴嘴是大嘴007完成签到,获得积分10
9秒前
无奈的萍完成签到,获得积分10
10秒前
李大胖胖完成签到 ,获得积分0
11秒前
feiyang完成签到 ,获得积分0
12秒前
chen完成签到 ,获得积分10
13秒前
兴奋的天蓉完成签到 ,获得积分10
13秒前
愉快的友绿完成签到 ,获得积分10
14秒前
Xccc发布了新的文献求助10
15秒前
yang完成签到 ,获得积分10
16秒前
苗条的访冬完成签到 ,获得积分10
16秒前
英俊的铭的应助被活泼雪莲采纳,获得10
16秒前
卞卞完成签到,获得积分10
16秒前
趙途嘵生完成签到,获得积分10
18秒前
lyra1111完成签到,获得积分10
19秒前
23秒前
火星上的山河完成签到 ,获得积分10
24秒前
风趣的月光完成签到 ,获得积分10
25秒前
寒冷的映冬完成签到,获得积分10
25秒前
film完成签到 ,获得积分10
30秒前
arch完成签到,获得积分10
31秒前
酷炫大白完成签到,获得积分10
31秒前
兰先生完成签到,获得积分10
31秒前
欣喜烙完成签到 ,获得积分10
32秒前
32秒前
机智铭完成签到,获得积分10
33秒前
龙阿完成签到 ,获得积分10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923